Abstract
Neurogenic lower urinary tract dysfunction (NLUTD) is the accepted terminology used to describe bladder symptoms and dysfunction with neurogenic bladder (NGB). The patterns of NLUTD are varied and can span benign overactive bladder resulting in simple incontinence to a high-pressure bladder causing urosepsis, hydronephrosis, and renal failure. The degree and type of NLUTD depends upon the etiology underlying NGB, the severity of the disease or injury, and where and how the nervous system is affected. In this chapter, we will summarize common medical and surgical treatments for NLUTD.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Gajewski JB, Drake MJ. Neurological lower urinary tract dysfunction essential terminology. Neurourol Urodyn. 2018;37(S6):S25–31.
Manchana T, Prasartsakulchai C. Bethanechol chloride for the prevention of bladder dysfunction after radical hysterectomy in gynecologic cancer patients: a randomized controlled trial study. Int J Gynecol Cancer. 2011;21(4):730–6.
Yamaguchi O. Antimuscarinics and overactive bladder: other mechanism of action. Neurourol Urodyn. 2010;29(1):112–5.
Hadiji N, et al. Are oxybutynin and trospium efficacious in the treatment of detrusor overactivity in spinal cord injury patients? Spinal Cord. 2014;52(9):701–5.
Amarenco G, et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourol Urodyn. 2017;36(2):414–21.
Kennelly MJ, et al. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology. 2009;74(4):741–5.
Krhut J, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2018;37(7):2226–33.
Welk B, et al. A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 2018;37(8):2810–7.
Abrams P, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67(3):577–88.
Herschorn S, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;120(4):562–75.
Cameron AP, et al. Combination drug therapy improves compliance of the neurogenic bladder. J Urol. 2009;182(3):1062–7.
Weld KJ, Dmochowski RR. Effect of bladder management on urological complications in spinal cord injured patients. J Urol. 2000;163(3):768–72.
Cameron AP, et al. Medical and psychosocial complications associated with method of bladder management after traumatic spinal cord injury. Arch Phys Med Rehabil. 2011;92(3):449–56.
Anderson CE, et al. Bladder emptying method is the primary determinant of urinary tract infections in patients with spinal cord injury: results from a prospective rehabilitation cohort study. BJU Int. 2019;123(2):342–52.
Husmann DA, Rathbun SR. Long-term follow up of enteric bladder augmentations: the risk for malignancy. J Pediatr Urol. 2008;4(5):381–5. discussion 386
Higuchi TT, Fox JA, Husmann DA. Annual endoscopy and urine cytology for the surveillance of bladder tumors after enterocystoplasty for congenital bladder anomalies. J Urol. 2011;186(5):1791–5.
Higuchi TT, et al. Augmentation cystoplasty and risk of neoplasia: fact, fiction and controversy. J Urol. 2010;184(6):2492–6.
Consortium for Spinal Cord M. Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers. J Spinal Cord Med. 2006;29(5):527–73.
Welk B, et al. Bladder cancer in individuals with spinal cord injuries. Spinal Cord. 2013;51(7):516–21.
Kreydin E, et al. Surveillance and management of urologic complications after spinal cord injury. World J Urol. 2018;36(10):1545–53.
Katsumi HK, et al. Urethral versus suprapubic catheter: choosing the best bladder management for male spinal cord injury patients with indwelling catheters. Spinal Cord. 2010;48(4):325–9.
Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord. 2002;40(11):599–600.
Cruz F, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742–50.
Ginsberg D, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131–9.
Mehta S, et al. Meta-analysis of botulinum toxin a detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury. Arch Phys Med Rehabil. 2013;94(8):1473–81.
Del Popolo G, et al. Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre. Eur Urol. 2008;53(5):1013–9.
Kennelly M, et al. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: final results of a long-term extension study. Neurourol Urodyn. 2017;36(2):368–75.
Quek ML, Ginsberg DA. Long-term urodynamics followup of bladder augmentation for neurogenic bladder. J Urol. 2003;169(1):195–8.
Myers JB, et al. The effects of augmentation cystoplasty and botulinum toxin injection on patient-reported bladder function and quality of life among individuals with spinal cord injury performing clean intermittent catheterization. Neurourol Urodyn. 2019;38(1):285–94.
Redshaw JD, et al. Procedures needed to maintain functionality of adult continent catheterizable channels: a comparison of continent cutaneous ileal cecocystoplasty with tunneled catheterizable channels. J Urol. 2014;192(3):821–6.
Welk B, et al. Population based assessment of enterocystoplasty complications in adults. J Urol. 2012;188(2):464–9.
Metcalfe PD, et al. What is the need for additional bladder surgery after bladder augmentation in childhood? J Urol. 2006;176(4 Pt 2):1801–5. discussion 1805.
Rowland RG, Kropp BP. Evolution of the Indiana continent urinary reservoir. J Urol. 1994;152(6 Pt 2):2247–51.
Rowland RG, et al. Indiana continent urinary reservoir. J Urol. 1987;137(6):1136–9.
Bassett MR, et al. Urinary diversion for severe urinary adverse events of prostate radiation: results from a multi-institutional study. J Urol. 2017;197(3. Pt 1):744–50.
Myers JB, Lenherr SM. Perioperative and long-term surgical complications for the Indiana pouch and similar continent catheterizable urinary diversions. Curr Opin Urol. 2016;26(4):376–82.
Shimko MS, et al. Long-term complications of conduit urinary diversion. J Urol. 2011;185(2):562–7.
Madersbacher S, et al. Long-term outcome of ileal conduit diversion. J Urol. 2003;169(3):985–90.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Myers, J.B. (2020). Common Bladder Management Treatments for Patients with Neurogenic Bladder. In: Stoffel, J.T., Dray, E.V. (eds) Urological Care for Patients with Progressive Neurological Conditions. Springer, Cham. https://doi.org/10.1007/978-3-030-23277-1_8
Download citation
DOI: https://doi.org/10.1007/978-3-030-23277-1_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-23276-4
Online ISBN: 978-3-030-23277-1
eBook Packages: MedicineMedicine (R0)